Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Phase 4 Completed 40 enrolled Saint Luke's Health System Amylin Pharmaceuticals, LLC. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

Timeline

Start: 2008-08
Primary completion: 2011-06
Completion: 2012-08

Outcome

Mixed primary results

registry MEDIAN Exenatide: 132 (110 to 157) mg/dL MEDIAN Moderate: 127 (105 to 161) mg/dL NCT00736229 ↗

registry analysis (superiority or other test); Exenatide vs Moderate; p = 0.15; Wilcoxon (Mann-Whitney); note: Comparison of Median Glucose Values between Exenatide and Moderate Groups. NCT00736229 ↗

registry MEDIAN Exenatide: 2.0 (1.5 to 5.0) hours MEDIAN Moderate: 12.0 (7.0 to 15.0) hours NCT00736229 ↗

registry analysis (superiority or other test); Exenatide vs Moderate; p <0.001; Wilcoxon (Mann-Whitney) NCT00736229 ↗

Publications

Results Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, Marso SP. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013 Jan-Feb;19(1):81-90. doi: 10.4158/EP12196.OR.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	0.025 ug	Intravenous